Repligen (NASDAQ:RGEN) Shares Break Above Fifty Day Moving Average – What’s Next?

Posted by Brian Himes on Oct 27th, 2026

Repligen Corporation (NASDAQ:RGEN – Get Free Report)’s stock price passed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $177.37 and traded as high as $181.46. Repligen shares last traded at $180.17, with a volume of 1,177,395 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on RGEN shares. Wells Fargo & Company upped their target price on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Zacks Research lowered shares of Repligen from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. UBS Group reissued a “buy” rating on shares of Repligen in a report on Tuesday, September 29th. Finally, Canaccord Genuity Group increased their price objective on shares of Repligen from $145.00 to $180.00 and gave the company a “hold” rating in a research report on Monday, October 19th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $175.71.

View Our Latest Report on Repligen

Repligen Stock Performance

The company has a market cap of $10.17 billion, a P/E ratio of 246.81, a PEG ratio of 3.23 and a beta of 1.08. The business’s 50 day simple moving average is $177.37 and its 200 day simple moving average is $144.96. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN – Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.26 earnings per share. Sell-side analysts predict that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. United Capital Financial Advisors LLC bought a new position in Repligen in the 2nd quarter worth $380,756,000. Maverick Capital Ltd. bought a new stake in Repligen during the first quarter valued at about $178,946,000. William Blair Investment Management LLC bought a new stake in Repligen during the second quarter valued at about $107,593,000. Bamco Inc. NY purchased a new position in shares of Repligen in the second quarter valued at about $102,121,000. Finally, TimesSquare Capital Management LLC purchased a new position in shares of Repligen in the second quarter valued at about $60,984,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

(Get Free Report)

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.